Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice

Stefan Nierkens, Martijn H. den Brok, Thijs Roelofsen et al. · 2009

Read Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice by Stefan Nierkens, Martijn H. den Brok, Thijs Roelofsen et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0008368.txt.

Description

Stefan Nierkens and colleagues tested cancer immunotherapy routes in mice in a PLOS ONE paper from 2009. CpG is an agonist of TLR9, a sensor that sparks immune defenses. It is increasingly applied to enhance tumor immunity in studies and trials. Clinical success, however, has lagged behind animal results. One reason might be differing routes of administration.

The route of giving CpG critically determined therapy efficacy in mice. How a drug enters the body can change which immune cells it reaches. Matching the mouse route to human use may improve trial outcomes. The study is a practical lesson for immunotherapy design.

Catalog record

CREATORStefan Nierkens, Martijn H. den Brok, Thijs Roelofsen et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008368

Browse the full library · About the Tower of Babel